Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection

Gut

Volumn 65, Issue 10, 2016, Pages 1744-1753

  Keng, Choong Tat ^a   Sze, Ching Wooen ^b   Zheng, Dahai ^a   Zheng, Zhiqiang ^a   Yong, Kylie Su Mei ^a   Tan, Shu Qi ^c   Ong, Jessica Jie Ying ^a   Tan, Sue Yee ^a   Loh, Eva ^c   Upadya, Megha Haridas ^b   Kuick, Chik Hong ^c   Hotta, Hak ^d   Lim, Seng Gee ^e,f   Tan, Thiam Chye ^c,g   Chang, Kenneth T E ^c,g   Hong, Wanjin ^a   Chen, Jianzhu ^h,i   Tan, Yee Joo ^a,b   Chen, Qingfeng ^a,b,h  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Dept Medicine Endocrinol Diabet   (Singapore)

^f NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

^h SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYTOKINE; ALPHA INTERFERON; ANTIVIRUS AGENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; FETUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE FUNCTION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPRODUCIBILITY; SYMPTOM; T LYMPHOCYTE; ANIMAL; CELLULAR IMMUNITY; CHRONIC HEPATITIS C; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; INTERFERON-ALPHA; MICE; MICE, INBRED NOD; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84937605396     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307856     Document Type: Article

References (50)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
2. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol 2008;7:114-19.
3. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004;39:1469-75.
4. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52.
5. Legrand N, Ploss A, Balling R, et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009;6:5-9.
6. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012;142:1279-1287.e3.
7. Galun E, Burakova T, Ketzinel M, et al. Hepatitis C virus viremia in SCID-BNX mouse chimera. J Infect Dis 1995;172:25-30.
8. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-11.
9. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33.
10. Dorner M, Horwitz JA, Donovan BM, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013;501:237-41.
11. Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924-30.
12. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49.
13. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-55.
14. Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002;128:195-203.
15. Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334-44.
16. Bility MT, Cheng L, Zhang Z, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014;10:e1004032.
17. Chen Q, Khoury M, Limmon G, et al. Human fetal hepatic progenitor cells are distinct from, but closely related to, hematopoietic stem/progenitor cells. Stem Cells 2013;31:1160-9.
18. Carpentier A, Tesfaye A, Chu V, et al. Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest 2014;124:4953-64.
19. Schwartz RE, Fleming HE, Khetani SR, et al. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32:504-13.
20. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012;109:2544-8.
21. Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-40.
22. Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002;36:850-60.
23. Khakoo SI, Soni PN, Savage K, et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol 1997;150:963-70.
24. Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008;112:1620-7.
25. Polyak SJ, Khabar KS, Rezeiq M, et al. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001;75:6209-11.
26. Cicinnati VR, Kang J, Sotiropoulos GC, et al. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J Gen Virol 2008;89:1243-53.
27. Nishitsuji H, Funami K, Shimizu Y, et al. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 2013;87:8169-78.
28. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003;74:360-9.
29. Moura AS, Carmo RA, Teixeira AL, et al. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2010;29:1153-61.
30. Frucht DM, Fukao T, Bogdan C, et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001;22:556-60.
31. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81.
32. Frisdal E, Lesnik P, Olivier M, et al. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J Biol Chem 2011;286:30926-36.
33. Guidotti LG and Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
34. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
35. Cotler SJ, Reddy KR, McCone J, et al. An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. J Interferon Cytokine Res 2001;21:1011-19.
36. Malaguarnera M, Di Fazio I, Laurino A, et al. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-Alpha treatment. Int J Clin Pharmacol Ther 1997;35:385-8.
37. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-82.
38. Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma (null) mutation. Clin Immunol 2010;135:84-98.
39. Legrand N, Huntington ND, Nagasawa M, et al. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- And natural killer- (NK) cell homeostasis in vivo. Proc Natl Acad Sci U S A 2011;108:13224-9.
40. Bartolome J, Lopez-Alcorocho JM, Castillo I, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007;81:7710-15.
41. Dustin LB. Too low to measure, infectious nonetheless. Blood 2012;119:6181-2.
42. Castillo I, Pardo M, Bartolome J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
43. De Marco L, Gillio-Tos A, Fiano V, et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS ONE 2009; 4:e8128.
44. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
45. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007;25:71-99.
46. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-62.
47. Fallahi P, Ferri C, Ferrari SM, et al. Cytokines and HCV-related disorders. Clin Dev Immunol 2012;2012:468107.
48. Morita M, Watanabe Y, Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology 1995;21:1585-93.
49. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012;61:1226-34.
50. Pawlotsky JM. Treatment failure and resistance with direct-Acting antiviral drugs against hepatitis C virus. Hepatology 2011;53:1742-51.